Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Novo-Nordisk News

    116,56 € -1,22% -1,44 €
    20:52:51 Uhr Tradegate aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3EU6F
    ISIN: DK0062498333
    US-Symbol: NONOF
    Typ: Aktie
    Werbung
    Weiter abwärts?
    Short Hebel 6,62
    VM9171

    Ad-hocs

    24.04.24 - GlobeNewswire
    Novo Nordisk A/S – Reduction of the share capital
    Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to ...
    21.03.24 - GlobeNewswire
    Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
    Bagsværd, Denmark, 21 March 2024 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted ...
    21.03.24 - GlobeNewswire
    Resolutions from the Annual General Meeting of Novo Nordisk A/S
    Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting.
    08.03.24 - GlobeNewswire
    Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
    Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a ...
    07.03.24 - GlobeNewswire
    Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
    Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025.
    05.03.24 - GlobeNewswire
    Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
    Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop ...
    21.02.24 - GlobeNewswire
    Notice for the Annual General Meeting of Novo Nordisk A/S
    Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on:
    05.02.24 - GlobeNewswire
    Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction
    Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-​finish sites from Novo Holdings A/S (Novo Holdings) in ...
    31.01.24 - GlobeNewswire
    Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
    Bagsværd, Denmark, 31 January 2024 - Financial report for the period 1 January 2023 to 31 December 2023
    08.01.24 - GlobeNewswire
    COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes
    COMBINE 3 phase 3a trial successfully completed with once-​weekly IcoSema demonstrating non-​inferior reduction in HbA 1c versus daily basal-​bolus treatment (insulin glargine ...
    02.11.23 - GlobeNewswire
    Novo Nordisk's sales increased by 29% in Danish kroner and by 33% at constant exchange rates to DKK 166.4 billion in the first nine months of 2023
    Bagsværd 2 November 2023 - Financial report for the period 1 January 2023 to 30 September 2023
    13.09.23 - GlobeNewswire
    Novo Nordisk conducts a two-for-one stock split
    Bagsværd, Denmark, 13 September 2023 – As communicated on 10 August 2023 in connection with the release of Novo Nordisk's financial results for the first six months of 2023, ...
    10.08.23 - GlobeNewswire
    Novo Nordisk's sales increased by 29% in Danish kroner and by 30% at constant exchange rates to DKK 107.7 billion in the first six months of 2023
    Financial report for the period 1 January 2023 to 30 June 2023, 10 August 2023
    08.08.23 - GlobeNewswire
    Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
    Bagsværd, Denmark , 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-​blinded trial compared ...
    22.05.23 - GlobeNewswire
    Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
    Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy ...
    04.05.23 - GlobeNewswire
    Novo Nordisk's sales increased by 27% in Danish kroner and by 25% at constant exchange rates to DKK 53.4 billion in the first three months of 2023
    Financial report for the period 1 January 2023 to 31 March 2023
    28.04.23 - GlobeNewswire
    Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2023
    Bagsværd , Denmark, 2 8 April 202 3 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and ...
    26.04.23 - GlobeNewswire
    Novo Nordisk A/S – Reduction of the share capital
    Bagsværd , Denmark, 2 6 April 202 3 – At Novo Nordisk’s Annual General Meeting on 23 March 2023, it was decided to reduce the company’s B share capital from DKK 348,512,800 to ...
    13.04.23 - GlobeNewswire
    Novo Nordisk raises sales and operating profit outlook for 2023
    Bagsværd, Denmark, 13 April 2023 – Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months of 2023 and ...
    24.03.23 - GlobeNewswire
    Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial
    Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-​daily ...

    Newssuche

    Videos

    newspaper
    09:30 Uhr +26,02%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »